It’s a bit cryptic …
From the quarterly on the 30th Jan it was said ….
“There were preliminary signs of efficacy from the 14 patients dosed in the Phase 1b trial.”
From today’s Ann …
Of these fourteen patients seven (7) patients remained on trial for >6 months, with two (2)
patients being on trial for more than 10 months.
Six (6) patients have now recorded a partial response as best response, with the remaining
eight (8) recording stable disease.
6 and 8 presumably that’s the 14 patients in question from 1b trail
No mention of any deaths …
These response rates are substantially higher than predicted from historical studies of
gemcitabine and Abraxane treatment alone.
And importantly, … Three (3) patients remain on trial from the Phase 1b cohort.
.
- Forums
- ASX - By Stock
- ATX
- Ann: Update on ACCENT Trial in Pancreatic Cancer
Ann: Update on ACCENT Trial in Pancreatic Cancer, page-7
-
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ATX (ASX) to my watchlist
(20min delay)
|
|||||
Last
6.0¢ |
Change
-0.007(10.5%) |
Mkt cap ! $17.65M |
Open | High | Low | Value | Volume |
6.5¢ | 6.5¢ | 6.0¢ | $22.25K | 356.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 17358 | 5.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.0¢ | 87036 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 17358 | 0.058 |
1 | 79000 | 0.057 |
1 | 17978 | 0.056 |
4 | 356818 | 0.055 |
1 | 18520 | 0.054 |
Price($) | Vol. | No. |
---|---|---|
0.060 | 87036 | 2 |
0.061 | 248803 | 1 |
0.062 | 40158 | 2 |
0.066 | 166989 | 2 |
0.067 | 121201 | 2 |
Last trade - 13.30pm 20/06/2024 (20 minute delay) ? |
Featured News
ATX (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online